Ensysce Biosciences (ENSC) Research & Development (2020 - 2025)
Ensysce Biosciences (ENSC) posted quarterly Research & Development of $3.0 million for Q3 2025, up 74.78% year-over-year from $1.7 million in Q3 2024, and up 53.63% quarter-over-quarter from $1.9 million in Q2 2025.
Ensysce Biosciences (ENSC) Research & Development (2020 - 2025) Analysis & Trends
Ensysce Biosciences (ENSC) has reported Research & Development for 6 consecutive years, with $3.0 million the latest figure, recorded in Q3 2025.
- In Q3 2025, Research & Development rose 74.78% year-over-year to $3.0 million; the TTM figure through Sep 2025 stood at $10.6 million (up 87.03% YoY), while the FY2024 annual figure was $7.2 million, down 4.85% from the prior year.
- Research & Development grew to $3.0 million in Q3 2025 per ENSC's latest filing, from $1.9 million in the prior quarter.
- Across five years, Research & Development topped out at $6.4 million in Q4 2022 and bottomed at $284378.0 in Q1 2021.
- Historically, Research & Development has averaged $2.4 million across 5 years, with a median of $1.9 million in 2023.
- Annual changes were most pronounced in 2022 — Research & Development soared 1046.61% — and 2023, when it sank 69.05%.
- Ensysce Biosciences' Research & Development stood at $2.2 million in 2021, then soared by 194.44% to $6.4 million in 2022, then sank by 65.34% to $2.2 million in 2023, then jumped by 70.31% to $3.8 million in 2024, then retreated by 22.29% to $3.0 million in 2025.
- Business Quant data shows ENSC's Research & Development at $3.0 million in Q3 2025, $1.9 million in Q2 2025, and $1.9 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 413.13 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -588.31 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 210.03 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 97.90 Mn |
| 10 | Ensysce Biosciences | 942,649.19 | -3.37 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 2.95 Mn |
| Jun 30, 2025 | 1.92 Mn |
| Mar 31, 2025 | 1.89 Mn |
| Dec 31, 2024 | 3.80 Mn |
| Sep 30, 2024 | 1.69 Mn |
| Jun 30, 2024 | 947,229.00 |
| Mar 31, 2024 | 778,904.00 |
| Dec 31, 2023 | 2.23 Mn |
| Sep 30, 2023 | 1.91 Mn |
| Jun 30, 2023 | 1.64 Mn |
| Mar 31, 2023 | 1.80 Mn |
| Dec 31, 2022 | 6.44 Mn |
| Sep 30, 2022 | 4.76 Mn |
| Jun 30, 2022 | 5.31 Mn |
| Mar 31, 2022 | 3.14 Mn |
| Dec 31, 2021 | 2.19 Mn |
| Sep 30, 2021 | 1.71 Mn |
| Jun 30, 2021 | 463,219.00 |
| Mar 31, 2021 | 284,378.00 |
| Dec 31, 2020 | 1.25 Mn |